Erasca to Present at the 43rd Annual J.P. Morgan Healthcare Conference
| ERAS Stock | USD 1.93 0.03 1.58% |
Slightly above 50% of Erasca's private investors are presently thinking to get in. The analysis of the overall investor sentiment regarding Erasca Inc suggests that some traders are interested. Erasca's investing sentiment can be driven by a variety of factors including economic data, Erasca's earnings reports, geopolitical events, and overall market trends.
Erasca |
SAN DIEGO, Jan. 07, 2025 -- Erasca, Inc. , a clinical-stage precision oncology company singularly focused on discovering, developing,
Read at gurufocus.com
 |
Erasca Fundamental Analysis
We analyze Erasca's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Erasca using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Erasca based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Erasca is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Erasca Inc Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Erasca stock to make a market-neutral strategy. Peer analysis of Erasca could also be used in its relative valuation, which is a method of valuing Erasca by comparing valuation metrics with similar companies.
Peers
Erasca Related Equities
| DSGN | Design Therapeutics | 6.37 | ||||
| STOK | Stoke Therapeutics | 5.79 | ||||
| RLAY | Relay Therapeutics | 5.58 | ||||
| KROS | Keros Therapeutics | 5.53 | ||||
| OLMA | Olema Pharmaceuticals | 3.27 | ||||
| IPSC | Century Therapeutics | 2.25 | ||||
| PLRX | Pliant Therapeutics | 2.01 | ||||
| CCCC | C4 Therapeutics | 0.81 | ||||
| MLYS | Mineralys Therapeutics, | 0.69 | ||||
| CGEM | Cullinan Oncology | 0.48 | ||||
| ZNTL | Zentalis Pharmaceuticals | 0.44 | ||||
| SANA | Sana Biotechnology | 0.29 | ||||
| EWTX | Edgewise Therapeutics | 0.52 | ||||
| GLUE | Monte Rosa | 0.54 | ||||
| ARVN | Arvinas | 1.88 | ||||
| BDTX | Black Diamond | 4.21 |
Additional Tools for Erasca Stock Analysis
When running Erasca's price analysis, check to measure Erasca's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Erasca is operating at the current time. Most of Erasca's value examination focuses on studying past and present price action to predict the probability of Erasca's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Erasca's price. Additionally, you may evaluate how the addition of Erasca to your portfolios can decrease your overall portfolio volatility.